NASDAQ:QURE uniQure (QURE) Stock Price, News & Analysis $13.49 -0.51 (-3.64%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$13.28 -0.22 (-1.59%) As of 08/6/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About uniQure Stock (NASDAQ:QURE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get uniQure alerts:Sign Up Key Stats Today's Range$13.31▼$13.9450-Day Range$13.49▼$17.2752-Week Range$4.45▼$19.18Volume714,522 shsAverage Volume1.40 million shsMarket Capitalization$740.20 millionP/E RatioN/ADividend YieldN/APrice Target$36.55Consensus RatingModerate Buy Company Overview uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Read More uniQure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreQURE MarketRank™: uniQure scored higher than 48% of companies evaluated by MarketBeat, and ranked 1096th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatinguniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageuniQure has only been the subject of 4 research reports in the past 90 days.Read more about uniQure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($3.75) to ($3.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.75% of the outstanding shares of uniQure have been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in uniQure has recently decreased by 1.03%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.75% of the outstanding shares of uniQure have been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in uniQure has recently decreased by 1.03%, indicating that investor sentiment is improving. News and Social Media1.8 / 5News Sentiment0.26 News SentimentuniQure has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for uniQure this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $322,426.00 in company stock.Percentage Held by InsidersOnly 4.79% of the stock of uniQure is held by insiders.Percentage Held by Institutions78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about uniQure's insider trading history. Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Email Address QURE Stock News HeadlinesuniQure (NASDAQ:QURE) Upgraded at Wall Street ZenAugust 4 at 2:41 AM | americanbankingnews.comCantor Fitzgerald Predicts Weaker Earnings for uniQureAugust 3, 2025 | americanbankingnews.comOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast. | InvestorPlace (Ad)Leerink Partnrs Has Bullish Estimate for uniQure Q3 EarningsAugust 3, 2025 | americanbankingnews.comWilliam Blair Has Positive Outlook for uniQure Q3 EarningsAugust 3, 2025 | americanbankingnews.comWhat is HC Wainwright's Forecast for uniQure Q3 Earnings?August 2, 2025 | americanbankingnews.comFY2027 Earnings Forecast for uniQure Issued By HC WainwrightAugust 1, 2025 | americanbankingnews.comLeerink Partnrs Has Bullish Outlook for uniQure Q4 EarningsAugust 1, 2025 | americanbankingnews.comSee More Headlines QURE Stock Analysis - Frequently Asked Questions How have QURE shares performed this year? uniQure's stock was trading at $17.66 on January 1st, 2025. Since then, QURE stock has decreased by 23.6% and is now trading at $13.49. How were uniQure's earnings last quarter? uniQure N.V. (NASDAQ:QURE) issued its quarterly earnings data on Tuesday, July, 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.20. The biotechnology company had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5 million. uniQure had a negative net margin of 1,387.98% and a negative trailing twelve-month return on equity of 1,010.74%. Read the conference call transcript. Who are uniQure's major shareholders? uniQure's top institutional investors include Aberdeen Group plc (5.02%), Privium Fund Management B.V. (0.82%), Jennison Associates LLC (0.26%) and Simplex Trading LLC. Insiders that own company stock include Matthew C Kapusta, Christian Klemt, Ricardo Dolmetsch, Walid Abi-Saab, Jeannette Potts, Alexander Edward Kuta III, Pierre Caloz, Robert Gut, Madhavan Balachandran, Jeremy P Springhorn, David D Meek, Leonard E Post, Rachelle Suzanne Jacques, Jack Kaye and Paula Soteropoulos. View institutional ownership trends. How do I buy shares of uniQure? Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some other companies that uniQure investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings7/29/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QURE CIK1590560 Webwww.uniqure.com Phone(120) 240-6000Fax31-20-566-9272Employees500Year FoundedN/APrice Target and Rating Average Price Target for uniQure$36.55 High Price Target$70.00 Low Price Target$20.00 Potential Upside/Downside+170.9%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$239.56 million Net Margins-1,387.98% Pretax Margin-1,375.80% Return on Equity-1,010.74% Return on Assets-33.27% Debt Debt-to-Equity Ratio1.53 Current Ratio9.98 Quick Ratio9.98 Sales & Book Value Annual Sales$27.12 million Price / Sales27.29 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-192.71Miscellaneous Outstanding Shares54,870,000Free Float52,239,000Market Cap$740.20 million OptionableOptionable Beta0.11 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:QURE) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.